D8517
鉄-デキストラン
95-105 mg/mL (Iron content), solution
別名:
水酸化第二鉄デキストラン複合体
SMILES string
[Fe].[S](=O)(=O)(O)O
InChI
1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)
InChI key
MVZXTUSAYBWAAM-UHFFFAOYSA-N
biological source
synthetic
sterility
aseptically filled
assay
95-105 mg/mL (Iron content)
form
solution
contains
0.5% phenol as preservative
composition
Iron, ~100 mg/mL
color
brown
useful pH range
4 - 6.5
storage temp.
room temp
Quality Level
signalword
Danger
hcodes
Hazard Classifications
Carc. 1B - Skin Sens. 1
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
名称等を表示すべき危険物及び有害物
ishl_indicated
名称等を通知すべき危険物及び有害物
ishl_notified
D8517-BULK: + D8517PROC: + D8517-PPG: + D8517-25ML-PW: + D8517-100ML-PW: + D8517-VAR: + D8517-100ML:4548174008478 + D8517-25ML:4548174008485 + D8517-PH:
jan
V J Kumpf et al.
DICP : the annals of pharmacotherapy, 24(2), 162-166 (1990-02-01)
Parenteral iron therapy is indicated in patients with iron-deficiency anemia associated with conditions that interfere with the ingestion or absorption of oral iron. Replacement doses of iron required to replenish iron stores are based on body weight and the observed
I V Alenkina et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 100, 88-93 (2012-04-03)
Application of Mössbauer spectroscopy with a high velocity resolution (4096 channels) for comparative analysis of iron cores in a human liver ferritin and its pharmaceutically important models Imferon, Maltofer(®) and Ferrum Lek as well as in iron storage proteins in
Zachariah DeFilipp et al.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 9(1), 129-132 (2012-08-08)
Iron deficiency is a major postoperative complication of Roux-en-Y gastric bypass surgery. Oral replacement can fail to correct the deficiency. Thus, recourse to parenteral iron administration might be necessary. Our objective was to evaluate the effectiveness and safety of a
D L Burns et al.
Nutrition (Burbank, Los Angeles County, Calif.), 11(2), 163-168 (1995-03-01)
Iron dextran was introduced more than 30 yr ago for the parenteral treatment of iron deficiency anemia that is refractory to oral therapy. Iron dextran is a preparation of ferric hydroxide complexed with a low molecular weight fraction of dextran.
Markus R Jahn et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 78(3), 480-491 (2011-03-29)
The treatment of iron deficiency anemia with polynuclear iron formulations is an established therapy in patients with chronic kidney disease but also in other disease areas like gastroenterology, cardiology, oncology, pre/post operatively and obstetrics' and gynecology. Parenteral iron formulations represent
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）